Published in Gene Therapy Weekly, June 15th, 2006
"To develop CpG ODNs based therapy for prevention and treatment of SARS, we selected a novel CpG ODN (BW001), which displays B-type CpG ODN structure feature at the 5' and A-type CpG ODN structure feature at the 3' and tested for its anti-SARS-CoV activity," wrote M.S. Bao and colleagues of Jilin University.
"We found that the supernatants of human PBMCs...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.